Seer, Inc. (SEER) Stock Analysis and Metrics

Seer

NASDAQ: SEER

$2.08 ▼ -0.02 (-0.95%)

At close: Aug 14, 2026 · 4:00 PM UTC

Financial Ratios

Market Cap230.63 Mn

P/E-2.19

P/S16.22

Div. Yield0.00

Add ratio to table…

About

Seer, Inc. develops and commercializes the Proteograph Product Suite, an integrated solution for unbiased, deep, and large-scale proteomic analysis. The company’s technology enables researchers to study the proteome at peptide-level resolution, capturing protein variants, post-translational modifications, and interactions without reliance on predefined binding epitopes. This approach supports applications in basic research, biomarker discovery, translational science, and multi-omic diagnostic development across academic, biopharmaceutical, and clinical research settings.

Seer generates revenue primarily through the sale of the Proteograph Product Suite, which includes consumable assays, the SP200 automation instrument, and the Proteograph Analysis Suite (PAS) software. Consumables such as the Proteograph ONE assay and Proteograph DIRECT assay are sold on a recurring basis, while the SP200 instrument is offered via direct purchase or through the Strategic Instrument Placement Program (SIPP), which allows customers to access the instrument with minimal upfront capital. The company also provides fee-for-service access through its Seer Technology Access Centers (STACs) and collaborates with service providers and channel partners to expand accessibility.

The company operates through the following segments:

• Proteograph Product Suite: This segment encompasses the core consumables, automation instrumentation, and software that enable unbiased, deep proteomic analysis at scale. The Proteograph ONE assay, launched in May 2025, delivers approximately a ten-fold improvement in throughput over the original assay, allowing processing of more than 1,000 samples per week. The SP200 automation instrument, also launched in May 2025, supports population-scale studies through highly parallel sample processing with approximately 60 minutes of setup time. The Proteograph Analysis Suite (PAS) provides cloud-based data analytics for quality control, data management, and interpretation, including a dedicated proteogenomics workflow that maps peptide-level data to genomic data.

• Seer Technology Access Center (STAC): This segment provides fee-for-service access to the Proteograph workflow coupled with Thermo Scientific Orbitrap Astral MS instrumentation. The STAC lowers barriers to access for customers seeking high-quality proteomic data without requiring capital investment in equipment or expertise. The first STAC location launched in June 2023, with a second site opened in Bonn, Germany, in May 2024, in partnership with LIFE & BRAIN GmbH. STACs support researchers who want to leverage the Proteograph platform for discovery, translational, and clinical research applications on a pay-per-use basis.

Seer occupies a leading position in the proteomics market by offering the only commercially available platform that combines unbiased sampling, deep coverage, high reproducibility, and scalability for population-scale studies. The company differentiates itself from affinity-based proteomic methods, which are prone to epitope effects and false-positive signals, by delivering peptide-level resolution that enables accurate detection of protein variants and post-translational modifications. Competitors include Agilent Technologies, Bio-Techne, Bruker, Danaher, Illumina, Thermo Fisher Scientific, and emerging growth companies such as Nautilus Biotechnology and Quanterix, none of which currently offer a fully integrated solution with comparable depth, throughput, and unbiased access to the proteome at scale.

Seer serves a global customer base of more than 190 customers across over 20 countries, including leading academic institutions, biopharmaceutical companies, biobanks, and clinical research organizations. Notable collaborators include Korea University for a 20,000-subject proteomics biomarker discovery study, Discovery Life Sciences for a human cadaver multi-organ proteomic benchmarking study exceeding 10,000 samples, and PrognomiQ, which has leveraged Proteograph data to develop ProVue Lung, a blood-based test for early lung cancer detection. The company also works with Massachusetts General Hospital on Alzheimer’s disease research and engages with Thermo Fisher Scientific through a co-marketing and sales agreement to expand access to its technology worldwide.

Investment Thesis

▲ Bull case

Despite near-term headwinds in academic funding and competitive pressures from imitators, Seer's foundational technology is gaining critical validation through high-impact publications and strategic biobank partnerships that signal long-term market leadership, with 84 peer-reviewed publications validating the Proteograph platform—up from 42 just one year ago—demonstrating accelerating scientific credibility that is underpinning real-world utility in early disease detection, such as PrognomIQ's breakthrough lung cancer study where the Proteograph-enabled blood test achieved 89% sensitivity across all stages and 83% sensitivity for stage 1 lung cancer in a cohort of 78 high-risk adults, results that could disrupt the low-compliance standard of low-dose CT screening and open a major translational pathway for proteomics in oncology; this validation is not merely academic but is directly translating into clinical utility, creating a defensible moat that imitators cannot replicate due to Seer's deep expertise in nanoparticle-based enrichment and its 250+ patent portfolio, 84 of which are issued, including key claims upheld by the PTAB, reinforcing that the company's intellectual property is not just broad but battle-tested and essential to maintaining trust with high-value customers like biobanks and pharma partners who cannot afford compromised data from inferior alternatives; the emergence of copycat products, while a near-term pricing pressure, actually validates the market Seer pioneered and highlights the performance gap that protects its core customer relationships in regulated, sample-sensitive environments.
Seer is strategically positioning itself at the inflection point of population-scale proteomics through landmark biobank collaborations like PRECISE-SG100K with Thermo Fisher and Precision Health Research, Singapore, which aims to generate deep unbiased proteomics data for 10,000 participants with potential expansion to 100,000—creating one of the world's largest multi-omics datasets—and the Korea University study, where initial data from a 20,000-patient cohort will be presented at ASMS in June and used to train a foundation AI model, signaling that Seer's technology is becoming the indispensable engine for next-generation biomedical discovery; these studies are not just scientific exercises but are designed to produce public, high-impact datasets that will demonstrate the Proteograph's unique ability to deliver standardized, deep, unbiased proteomics at scale—a capability conventional mass spectrometry cannot match—and when this data is shared publicly at forums like HUPO in September, it will serve as a powerful catalyst for broader adoption, triggering a flywheel effect where increased utilization drives more data generation, which in turn attracts more users and investment, particularly as Seer's next-generation detector and Raviant DIA analytical engine lower barriers to entry for multi-omic and AI-driven workflows, expanding the addressable market beyond traditional proteomics users into genomics and clinical research communities.
The appointment of Tony Bazarko as Chief Commercial Officer represents a deliberate and underappreciated catalyst that could unlock Seer's commercial potential after years of scientific validation, bringing two decades of proven leadership in scaling life sciences and diagnostics companies—including successful exits at Biologis (acquired by Ampersand) and Specific Diagnostics (acquired by bioMérieux)—with a specific mandate to translate Seer's strong science and biobank traction into commercial momentum by targeting high-impact segments like biopharma development through the evolved Insight Grant Program, which now features a translational research track and a new biopharma development track designed to engage pharma teams directly in mechanism of action, resistance biology, and biomarker strategy workflows where proteomics delivers immediate value; this structured approach lowers barriers to entry for new customers while generating high-quality data that fuels publications and long-term relationships, and with geographic expansion into underpenetrated segments, the program is poised to drive adoption in areas where Seer remains underutilized, setting the stage for a second-half 2026 revenue acceleration as instrument placements from 2025 begin to drive consumable pull-through on their 9–12 month cycle, a trend management highlighted as a key confidence factor in maintaining the $16–$18 million full-year guidance despite a soft Q1.
Seer's financial discipline and capital structure provide significant downside protection and optionality, with $219.5 million in cash, cash equivalents, and investments as of March 31, 2026, sufficient to fund operations to cash flow breakeven without dilution, while the company has already returned approximately $24.5 million to shareholders through its share repurchase program—reducing net shares outstanding by ~15% at a VWAP of $1.86—and recently authorized a new $25 million repurchase plan, signaling management's belief in deep undervaluation; this capital return, combined with tight operating expense control—reducing total OpEx from $22.8 million in Q1 2025 to $18.2 million in Q1 2026 despite ongoing investment in next-gen detector and software like Raviant DIA—demonstrates a commitment to efficiency that preserves runway for long-term bets, and at scale, Seer continues to target long-term gross margins of 70–75%, implying significant operating leverage as revenue scales, with current gross margin pressure viewed as temporary due to lower volume absorption of fixed costs, not structural weakness in the business model.

Despite near-term headwinds in academic funding and competitive pressures from imitators, Seer's foundational technology is gaining critical validation through high-impact publications and strategic biobank partnerships that signal long-term market leadership, with 84 peer-reviewed publications validating the Proteograph platform—up from 42 just one year ago—demonstrating accelerating scientific credibility that is underpinning real-world utility in early disease detection, such as PrognomIQ's breakthrough lung cancer study where the Proteograph-enabled blood test achieved 89% sensitivity across all stages and 83% sensitivity for stage 1 lung cancer in a cohort of 78 high-risk adults, results that could disrupt the low-compliance standard of low-dose CT screening and open a major translational pathway for proteomics in oncology; this validation is not merely academic but is directly translating into clinical utility, creating a defensible moat that imitators cannot replicate due to Seer's deep expertise in nanoparticle-based enrichment and its 250+ patent portfolio, 84 of which are issued, including key claims upheld by the PTAB, reinforcing that the company's intellectual property is not just broad but battle-tested and essential to maintaining trust with high-value customers like biobanks and pharma partners who cannot afford compromised data from inferior alternatives; the emergence of copycat products, while a near-term pricing pressure, actually validates the market Seer pioneered and highlights the performance gap that protects its core customer relationships in regulated, sample-sensitive environments.
Seer is strategically positioning itself at the inflection point of population-scale proteomics through landmark biobank collaborations like PRECISE-SG100K with Thermo Fisher and Precision Health Research, Singapore, which aims to generate deep unbiased proteomics data for 10,000 participants with potential expansion to 100,000—creating one of the world's largest multi-omics datasets—and the Korea University study, where initial data from a 20,000-patient cohort will be presented at ASMS in June and used to train a foundation AI model, signaling that Seer's technology is becoming the indispensable engine for next-generation biomedical discovery; these studies are not just scientific exercises but are designed to produce public, high-impact datasets that will demonstrate the Proteograph's unique ability to deliver standardized, deep, unbiased proteomics at scale—a capability conventional mass spectrometry cannot match—and when this data is shared publicly at forums like HUPO in September, it will serve as a powerful catalyst for broader adoption, triggering a flywheel effect where increased utilization drives more data generation, which in turn attracts more users and investment, particularly as Seer's next-generation detector and Raviant DIA analytical engine lower barriers to entry for multi-omic and AI-driven workflows, expanding the addressable market beyond traditional proteomics users into genomics and clinical research communities.
The appointment of Tony Bazarko as Chief Commercial Officer represents a deliberate and underappreciated catalyst that could unlock Seer's commercial potential after years of scientific validation, bringing two decades of proven leadership in scaling life sciences and diagnostics companies—including successful exits at Biologis (acquired by Ampersand) and Specific Diagnostics (acquired by bioMérieux)—with a specific mandate to translate Seer's strong science and biobank traction into commercial momentum by targeting high-impact segments like biopharma development through the evolved Insight Grant Program, which now features a translational research track and a new biopharma development track designed to engage pharma teams directly in mechanism of action, resistance biology, and biomarker strategy workflows where proteomics delivers immediate value; this structured approach lowers barriers to entry for new customers while generating high-quality data that fuels publications and long-term relationships, and with geographic expansion into underpenetrated segments, the program is poised to drive adoption in areas where Seer remains underutilized, setting the stage for a second-half 2026 revenue acceleration as instrument placements from 2025 begin to drive consumable pull-through on their 9–12 month cycle, a trend management highlighted as a key confidence factor in maintaining the $16–$18 million full-year guidance despite a soft Q1.
Seer's financial discipline and capital structure provide significant downside protection and optionality, with $219.5 million in cash, cash equivalents, and investments as of March 31, 2026, sufficient to fund operations to cash flow breakeven without dilution, while the company has already returned approximately $24.5 million to shareholders through its share repurchase program—reducing net shares outstanding by ~15% at a VWAP of $1.86—and recently authorized a new $25 million repurchase plan, signaling management's belief in deep undervaluation; this capital return, combined with tight operating expense control—reducing total OpEx from $22.8 million in Q1 2025 to $18.2 million in Q1 2026 despite ongoing investment in next-gen detector and software like Raviant DIA—demonstrates a commitment to efficiency that preserves runway for long-term bets, and at scale, Seer continues to target long-term gross margins of 70–75%, implying significant operating leverage as revenue scales, with current gross margin pressure viewed as temporary due to lower volume absorption of fixed costs, not structural weakness in the business model.

▼ Bear case

Seer's core business remains critically dependent on an unstable academic and government funding environment, with Q1 2026 revenue declining 33.3% year-over-year to $2.8 million—the lowest first-quarter level since 2021—and management acknowledging that the depressed academic funding landscape has been pressuring customer budgets for multiple quarters, a structural headwind that shows no signs of abating and directly undermines the disposable income-driven model of selling Proteograph instruments and consumables to research labs, where budget cycles are tight and purchasing decisions are highly sensitive to macroeconomic shifts, making sustained growth dependent on unpredictable grant cycles rather than organic commercial demand, and while the company points to instrument utilization and consumable pull-through as future drivers, this assumes a base of installed instruments that is not growing meaningfully—only 40% of Q1 instrument shipments went to prior STAC customers and 20% to SIPP users—indicating limited expansion of the active user base, and without new instrument placements driving recurring revenue, the business remains vulnerable to fluctuations in existing customer project timing.
Despite management's emphasis on scientific validation and biobank partnerships, Seer has failed to translate its technological leadership into meaningful revenue growth, reaffirming only 3% year-over-year revenue growth at the midpoint of its $16–$18 million FY26 guidance—a figure that implies near-stagnation and reflects a persistent inability to monetize its platform beyond niche research applications, with the company having burned nearly $16 million in cash during Q1 2026 alone while generating minimal top-line progress, a pattern consistent with its long-term history of destroying over $1 billion in investor capital across multiple ventures under CEO Omid Farokhzad's leadership, including BIND Therapeutics, Selecta Biosciences, Tarveda Therapeutics, and Senti Biosciences, raising serious questions about whether the current strategy is capable of delivering scalable, profitable growth or merely perpetuating a cycle of scientific promise without commercial execution, especially given that the company's stock has delivered a -97% total shareholder return since its IPO in December 2020, indicating that the market has already discounted its long-term prospects as fundamentally flawed.
The emergence of lower-cost imitators like Nanomix Biotechnology—against which Seer has filed a patent infringement suit—represents a tangible and growing threat to Seer's market position, particularly in price-sensitive segments, as these products undermine Seer's value proposition by offering superficially similar technology at significantly reduced prices, and while Seer argues its IP is superior and its customers value sample integrity, the fact that imitators are gaining traction suggests that Seer's differentiation may not be sufficient to withstand commoditization pressures, especially in academic settings where budget constraints are severe, and the company's reliance on litigation to defend its technology is a reactive and costly strategy that diverts resources from innovation and sales, with no guarantee of success in court or deterrence against future entrants, and the admission that these copycats have "inferior performance" does not negate their ability to capture price-sensitive customers, potentially eroding Seer's installed base and slowing adoption of its premium platform.
Seer's path to profitability remains unclear and increasingly distant, with Q1 2026 gross margin declining to 35% from 49% in the prior year period due to lower revenue absorption of fixed costs, and while management targets long-term gross margins of 70–75%, this assumes a scale of operations that has not materialized after years of effort, and the company's continued investment in next-generation detector development and software like Raviant DIA—while strategically sound—further delays profitability by increasing OpEx without near-term revenue offset, especially as the analytical tools like Raviant DIA are positioned to serve large cohort and biopharma workflows that remain nascent and unproven as revenue drivers, and the service business, which management views as a leading indicator for instrument placements, showed significant weakness in Q1 with STAC revenue declining due to absence of large projects, highlighting the lumpiness and unpredictability of this stream and raising doubts about its reliability as a growth engine, all of which suggests that Seer may require additional capital beyond its current $219.5 million cash balance to reach breakeven, despite management's optimism, particularly if revenue growth remains elusive and OpEx remains elevated during the innovation phase.

Seer's core business remains critically dependent on an unstable academic and government funding environment, with Q1 2026 revenue declining 33.3% year-over-year to $2.8 million—the lowest first-quarter level since 2021—and management acknowledging that the depressed academic funding landscape has been pressuring customer budgets for multiple quarters, a structural headwind that shows no signs of abating and directly undermines the disposable income-driven model of selling Proteograph instruments and consumables to research labs, where budget cycles are tight and purchasing decisions are highly sensitive to macroeconomic shifts, making sustained growth dependent on unpredictable grant cycles rather than organic commercial demand, and while the company points to instrument utilization and consumable pull-through as future drivers, this assumes a base of installed instruments that is not growing meaningfully—only 40% of Q1 instrument shipments went to prior STAC customers and 20% to SIPP users—indicating limited expansion of the active user base, and without new instrument placements driving recurring revenue, the business remains vulnerable to fluctuations in existing customer project timing.
Despite management's emphasis on scientific validation and biobank partnerships, Seer has failed to translate its technological leadership into meaningful revenue growth, reaffirming only 3% year-over-year revenue growth at the midpoint of its $16–$18 million FY26 guidance—a figure that implies near-stagnation and reflects a persistent inability to monetize its platform beyond niche research applications, with the company having burned nearly $16 million in cash during Q1 2026 alone while generating minimal top-line progress, a pattern consistent with its long-term history of destroying over $1 billion in investor capital across multiple ventures under CEO Omid Farokhzad's leadership, including BIND Therapeutics, Selecta Biosciences, Tarveda Therapeutics, and Senti Biosciences, raising serious questions about whether the current strategy is capable of delivering scalable, profitable growth or merely perpetuating a cycle of scientific promise without commercial execution, especially given that the company's stock has delivered a -97% total shareholder return since its IPO in December 2020, indicating that the market has already discounted its long-term prospects as fundamentally flawed.
The emergence of lower-cost imitators like Nanomix Biotechnology—against which Seer has filed a patent infringement suit—represents a tangible and growing threat to Seer's market position, particularly in price-sensitive segments, as these products undermine Seer's value proposition by offering superficially similar technology at significantly reduced prices, and while Seer argues its IP is superior and its customers value sample integrity, the fact that imitators are gaining traction suggests that Seer's differentiation may not be sufficient to withstand commoditization pressures, especially in academic settings where budget constraints are severe, and the company's reliance on litigation to defend its technology is a reactive and costly strategy that diverts resources from innovation and sales, with no guarantee of success in court or deterrence against future entrants, and the admission that these copycats have "inferior performance" does not negate their ability to capture price-sensitive customers, potentially eroding Seer's installed base and slowing adoption of its premium platform.
Seer's path to profitability remains unclear and increasingly distant, with Q1 2026 gross margin declining to 35% from 49% in the prior year period due to lower revenue absorption of fixed costs, and while management targets long-term gross margins of 70–75%, this assumes a scale of operations that has not materialized after years of effort, and the company's continued investment in next-generation detector development and software like Raviant DIA—while strategically sound—further delays profitability by increasing OpEx without near-term revenue offset, especially as the analytical tools like Raviant DIA are positioned to serve large cohort and biopharma workflows that remain nascent and unproven as revenue drivers, and the service business, which management views as a leading indicator for instrument placements, showed significant weakness in Q1 with STAC revenue declining due to absence of large projects, highlighting the lumpiness and unpredictability of this stream and raising doubts about its reliability as a growth engine, all of which suggests that Seer may require additional capital beyond its current $219.5 million cash balance to reach breakeven, despite management's optimism, particularly if revenue growth remains elusive and OpEx remains elevated during the innovation phase.

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	128.13 Bn	0.00 Mn	10.18	-
2	REGN	Regeneron Pharmaceuticals, Inc.	112.33 Bn	0.00 Mn	7.23	1.99 Bn
3	ARGX	Argenx Se	53.24 Bn	0.00 Mn	10.11	-
4	RVMD	Revolution Medicines, Inc.	43.64 Bn	0.00 Mn	-	-
5	ONC	BeOne Medicines Ltd.	39.27 Bn	0.00 Mn	6.41	1.07 Bn
6	HYFT	MindWalk Holdings Corp.	35.32 Bn	14.31 Mn	11.77	-
7	RPRX	Royalty Pharma plc	33.72 Bn	0.00 Mn	13.30	9.34 Bn
8	ALNY	Alnylam Pharmaceuticals, Inc.	30.58 Bn	0.00 Mn	6.36	-

Research Tools

Datasets

Plans

Developers

About

Investment Thesis

Peer Comparison

Research Tools

Datasets

Plans

Developers

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password